The epithelial-mesenchymal transition mediator S100A4 maintains cancer-initiating cells in head and neck cancers

JF Lo, CC Yu, SH Chiou, CY Huang, CI Jan, SC Lin… - Cancer research, 2011 - AACR
JF Lo, CC Yu, SH Chiou, CY Huang, CI Jan, SC Lin, CJ Liu, WY Hu, YH Yu
Cancer research, 2011AACR
Cancer-initiating cells (CIC) comprise a rare subpopulation of cells in tumors that are
proposed to be responsible for tumor growth. Starting from CICs identified in head and neck
squamous cell carcinomas (HNSCC), termed head and neck cancer-initiating cells (HN-
CIC), we determined as a candidate stemness-maintaining molecule for HN-CICs the
proinflammatory mediator S100A4, which is also known to be an inducer of epithelial-
mesenchymal transition. S100A4 knockdown in HN-CICs reduced their self-renewal …
Abstract
Cancer-initiating cells (CIC) comprise a rare subpopulation of cells in tumors that are proposed to be responsible for tumor growth. Starting from CICs identified in head and neck squamous cell carcinomas (HNSCC), termed head and neck cancer-initiating cells (HN-CIC), we determined as a candidate stemness-maintaining molecule for HN-CICs the proinflammatory mediator S100A4, which is also known to be an inducer of epithelial-mesenchymal transition. S100A4 knockdown in HN-CICs reduced their self-renewal capability and their stemness and tumorigenic properties, both in vitro and in vivo. Conversely, S100A4 overexpression in HNSCC cells enhanced their stem cell properties. Mechanistic investigations indicated that attenuation of endogenous S100A4 levels in HNSCC cells caused downregulation of Notch2 and PI3K (phosphoinositide 3-kinase)/pAKT along with upregulation of PTEN, consistent with biological findings. Immunohistochemical analysis of HNSCC clinical specimens showed that S100A4 expression was positively correlated with clinical grading, stemness markers, and poorer patient survival. Together, our findings reveal a crucial role for S100A4 signaling pathways in maintaining the stemness properties and tumorigenicity of HN-CICs. Furthermore, our findings suggest that targeting S100A4 signaling may offer a new targeted strategy for HNSCC treatment by eliminating HN-CICs. Cancer Res; 71(5); 1912–23. ©2010 AACR.
AACR